HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES

高效控制猕猴中的艾滋病病毒挑战

• 批准号: 8172951
• 负责人: Preston A Marx
• 金额: $ 6.18万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172951
• 关键词: Animals; Computer Retrieval of Information on Scientific Projects Database; Control Animal; Etiology; Exhibits; Functional disorder; Funding; Grant; Histology; Infection; Institution; Macaca; Macaca mulatta; Monitor; Neurologic Dysfunctions; Plasma; Protocols documentation; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Vaccines; Viral Load result; Virus; vector control

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Eighteen Rhesus macaques are assigned to one of three groups on this protocol. Animals were immunized with either empty vectors (controls), VSV/SFV E660 or VSV/SFV E660 + GMCSF in April, June and August 2009. All animals were challenged with SIVsmE660 in September 2009. All six animals receiving control vaccines became infected, with peak plasma viral loads ranging between 6.0 and 8.2 log copies/ml. PVL of three control animals has steadily declined after challenge (two of which are currently below detectable limits) and PVL of two control animals remains high between 6.0 and 7.0 log copies/ml. Finally one control animal was humanely euthanized due to neurologic dysfunction. The etiology of the dysfunction is not yet known (histology is pending). Five of the six animals receiving VSV/SFV E660 + GMCSF became infected with peak PVL ranging between 4.7 and 7.8 log copies/ml. One of these animals currently has PVL below detectable limits and the PVL of another animal in this group has steadily declined after challenge. Three animals exhibit PVL remaining steady between 4.0 and 6.0 log copies/ml. Two of six animals receiving VSV/SFV E660 became infected with peak PVL of 3.9 and 5.8 log copies/ml. The PVL of both of these animals returned to undetectable levels by day 35 and 42 post-challenge. All animals will continue to be monitored to follow the progression of infection or lack thereof.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 在该协议上，将十个恒河猕猴分配给三个组之一。 2009年4月，6月和8月，用空载体（对照组），VSV/SFV E660或VSV/SFV E660 + GMCSF对动物进行免疫。所有动物在2009年9月对SIVSME660挑战。 所有接受对照疫苗的六只动物都被感染，血浆病毒载荷范围为6.0至8.2 log Copies/ml。 在挑战之后（目前有两只对照限制的两只对照动物）的PVL稳步下降，两只对照动物的PVL在6.0和7.0 log Copies/ml之间保持较高。 最终，由于神经功能障碍，一只对照动物被人性化。 功能障碍的病因尚不清楚（组织学是待处理）。 接受VSV/SFV E660 + GMCSF的六只动物中有五只动物被峰值PVL感染，范围为4.7至7.8 log Copies/ml。 这些动物中的一只目前的PVL低于可检测的限制，而该组中另一只动物的PVL在挑战之后稳步下降。 三只动物表现出PVL在4.0和6.0 log副本/ml之间保持稳定。 接收VSV/SFV E660的六只动物中有两只被峰值PVL感染了3.9和5.8 log Copies/ml。 这两种动物的PVL在第35天和挑战后的第35天和42天都恢复了无法检测到的水平。 所有动物将继续受到监测，以遵循感染的进展或缺乏感染的进展。